Introduction: We assessed the additional effects of eplerenone to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on 24-h blood pressure (BP) level, fibrinolytic activity, and cardiovascular protection in elderly (>60 years) hypertensive patients. Materials and methods: In total, 20 patients (mean age 74 years, 25% men), whose BP was uncontrolled despite the use of anti-hypertensive drugs including ACEIs or ARBs (average 2.4 drugs), received eplerenone once daily (mean 37.5 mg) for 24 weeks. Results: Eplerenone treatment significantly reduced mean 24-h systolic/diastolic BP levels (143/80 mmHg to 132/74 mmHg, both p < 0.002). The reduction of 24-h systolic BP levels, especially night-time BP, was significantly associated with the reduction of atrial natriuretic peptide and brain natriuretic peptide levels (all p < 0.05). Furthermore, after eplerenone treatment, the mean plasminogen activator inhibitor-1 antigen level was significantly reduced (35 ng/ml to 25 ng/ml, p < 0.05), and the median level of plasma procollagen type III aminoterminal peptide and the urinary albumin excretion rate were also significantly reduced (0.8 U/ml to 0.6 U/ml, p < 0.003 and 53 mg/g·Cr to 23 mg/g·Cr, p < 0.05, respectively). During the intervention, eplerenone treatment was well tolerated with no reports of hyperkalaemia or hypotension. Conclusions: Addition of eplerenone to ACEIs or ARBs in elderly hypertensive patients offers significant benefits in terms of 24-h BP levels, fibrinolysis, and cardiovascular protection.
Introduction
Pharmacological blockade of the renin-angiotensinaldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) has become one of the most effective and widespread therapeutic approaches in the management of hypertension, because these agents represent a major opportunity for slowing the progression of cardiovascular diseases (CVDs) and, in turn, reducing the risk of morbidity and mortality. [1] [2] [3] The 2009 Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) recommend ACEIs or ARBs as a first-line therapy or as a cornerstone of combination therapy, especially in patients with multiple risk factors, including metabolic syndrome/diabetes, advanced age, chronic kidney disease, and heart diseases. 3 However, with regard to the blood pressure (BP) control achieved in treated hypertensive patients in our previous studies (J-MORE study, n = 969), 4 only about 20% of our outpatients were adequately controlled based on both office BP (systolic BP < 140 mmHg) and out-of-office BP (home systolic BP < 135 mmHg) measurement, although 60% of our outpatients were prescribed ACEIs or ARBs. Another large cross-sectional study conducted throughout Japan (n = 12,437) also demonstrated that only about 35% of hypertensive patients achieved adequate BP control (office BP < 140/90 mmHg) by monotherapy with ACEIs or ARBs. 5 Moreover, recent large clinical studies revealed that a considerable portion of high-risk patients had progression of CVDs or renal diseases despite using these therapies. 6, 7 Incomplete blockade of aldosterone (aldosterone breakthrough) was seen in roughly 30-40% of patients taking ACEIs or ARBs, 8, 9 which may be one of the explanations for the inadequate BP control or the inadequate cardiovascular protection by ACEIs or ARBs. In fact, Krum et al. 10 reported that in patients whose BP was not controlled by ACEIs or ARBs, the addition of 50-100 mg of eplerenone, a selective aldosterone blocker, significantly lowered office systolic/diastolic BP by -13/-10 mmHg (for eplerenone/ ACEIs) or -16/-13 mmHg (for eplerenone/ARBs) from baseline. However, the effects of eplerenone addition to ACEIs or ARBs on 24-h BP level and the diurnal BP variation among hypertensive patients, especially in elderly persons, remains unknown. Moreover, aldosterone not only contributes to salt and water homeostasis, but also exerts direct effects on prothrombotic states 11, 12 and cardiovascular and renal injury, 13, 14 which suggests that the combination of ACEIs or ARBs plus eplerenone treatment may offer more cardiovascular protection.
In the present study, we examined the additive effects of eplerenone on 24-h BP levels, fibrinolytic activity, and cardiovascular protection in Japanese elderly (> 60 years) hypertensive patients whose BP was not adequately controlled by anti-hypertensive drugs, including ACEIs or ARBs.
Materials and methods

Study population
This study was carried out at our outpatient clinic (Nango National Health Insurance Hospital, Miyazaki, Japan) from January 2009 to September 2009. This study was approved by the institutional review board at Jichi Medical University, and written informed consent was obtained from all the participants.
The enrolment criteria for this study included the following: (1) treated essential hypertension with office systolic and diastolic BP of more than 140/90 mmHg;
(2) treatment with ACEIs and ARBs at a stable dose for at least 6 months; and (3) no change in the use of other antihypertensive drugs, anti-hyperglycaemic drugs, or statins for at least 3 months. Exclusion criteria were: (1) baseline serum potassium > 5.0 mEq/l; (2) estimated glomerular filtration rate (eGFR) modified for Japanese < 50 ml/ min/1.73 m 2 ; 15 (3) severe liver dysfunction; (4) taking aldosterone antagonists or potassium-sparing diuretics;
(5) taking itraconazole, ritonavir, or nelfinavir; 6) diabetic patients with micro-or macroalbuminuria.
Study design
This study was designed to assess the efficacy and tolerability of eplerenone when added for the treatment of elderly hypertensive patients whose BP was not adequately controlled by ACEIs, ARBs, or other anti-hypertensive drugs. A low dose of eplerenone was used (25 mg or 50 mg once daily), because (1) Japanese drug information of eplerenone states that eplerenone should be used with caution in elderly persons or when co-administered with ACEIs or ARBs, because such cases are likely to have hyperkalaemia; and (2) low-dose spironolactone (12.5 mg to 50 mg once daily) may be sufficient to lower BP levels in patients with uncontrolled hypertension. 16 Our patients initially received eplerenone 25 mg/day, or eplerenone 50 mg/day if they had normal kidney function (eGFR > 90 ml/min/1.73 m 2 ). If office BP was still uncontrolled, the study medication was increased to eplerenone 50 mg/day.
At baseline and the study end (24 weeks after the start of treatment), office and 24-h BP levels, haemostasis and biochemical values, and urinalysis results were assessed. The serum potassium level was assessed in all patients at 2 weeks after the start of eplerenone treatment; if the serum potassium level was 5.5-5.9 mEq/l, the dose of eplerenone was halved; if the serum potassium level was > 6.0 mEq/l, the treatment of eplerenone was immediately stopped. Thereafter, additional tests were conducted to assess the serum potassium level, when a physician considered that follow-up examination was needed. During the intervention, if office systolic BP < 100 mmHg or symptomatic problems (e.g. dizziness, general fatigue) were observed, the dose of eplerenone was halved or stopped.
BP measurements
Office BP was measured by a digital oscillometric BP monitoring device (HEM-5041; Omron Healthcare Co. Ltd., Kyoto, Japan) while the subjects remained seated for 5 min, and values were calculated as the mean of three consecutive measures. 24-h ambulatory BP monitoring (TM-2425; A&D Co. Inc., Tokyo, Japan) was performed with an automatic oscillometric device at 30-min intervals. 17 All subjects used their prescribed anti-hypertensive medications as usual during 24-h BP monitoring, and all recorded their waking time as well as bedtime. We defined daytime and night-time BP as the average of values from each of these two periods. We sub-classified the patients according to the percentage of nocturnal systolic BP decline (100 × (1-nighttime systolic BP/daytime systolic BP)) as follows: dipping state, if the fall in BP was > 10%; non-dipping state if the fall in BP was < 10%.
Haemostasis and biochemical parameters measurements
Peripheral venous blood was obtained via a 21-gauge needle, with the patient in a fasting state, between 08:00 and 08:30 hours. All patients had rested in a supine position for at least 20 min before blood sampling. Plasma was obtained by centrifuging the whole blood at 1500× g for 15 min at 4°C, and samples were immediately frozen and stored at -40°C until used for analysis. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) antigen were assayed using an automated latex agglutination assay (LPIA·tPAI test; Mitsubishi Chemical Medience Co., Tokyo, Japan) based on conjugated monoclonal antibodies. The concentration of insulin (Lumipulse Presto II; FujiRevio Inc., Tokyo, Japan), renin (PRA TFB; TFB Inc., Tokyo, Japan), aldosterone (SPAC-S Aldosterone kit; TFB Inc., Tokyo, Japan), atrial natriuretic peptide (ANP) (MI02 Shionogi ANP; Shionogi Co., Osaka, Japan), and brain natriuretic peptide (BNP) (MI02 Shionogi BNP; Shionogi Co.) were measured by SRL Inc. (Tokyo, Japan). The intra-assay and inter-assay coefficients of the biochemical measurements were all < 10%. Type 2 diabetes was defined by the use of anti-hyperglycaemic drugs or a fasting glucose of &#8805; 126 mg/dl.
Cardiovascular parameter measurements
Plasma levels of procollagen type III aminoterminal peptide (PIIINP) (CIS Bio International, Nagoya, Japan), a marker of myocardial fibrosis, 18, 19 and procollagen type I C-terminal propeptide (ICTP) (Orion Diagnostic, Espoo, Finland), a marker of collagen type I synthesis and related to cardiac fibrosis in hypertensive patients, 20 were measured using radioimmunoassay. The urinary albumin excretion (UAE), a marker of not only renal dysfunction but also cardiovascular risks, was measured using an immunoturbidity kit (AutoWako Microalbumin; Wako Pure Chemical Industries, Ltd., Osaka, Japan), and was expressed as a creatinine ratio (mg/g·Cr). The intra-assay and interassay coefficients of the measurements were all < 7%.
Statistical analysis
All statistical analyses were performed with SPSS version 16.0J software (SPSS, Chicago, IL, USA). Data are expressed as the means + SD or median (25 th to 75 th percentile). Clinical parameters before and 24 weeks after treatment were compared using the paired Student's t-test for normally distributed variables, and the Wilcoxon test for variables with skewed distributions. Categorical parameters were compared with the chi-square test. The associations between the individual parameters were calculated using Pearson's correlation coefficients for normal variables, or Spearman's correlation coefficients for variables with skewed distributions. Values of p < 0.05 were considered to indicate statistical significance. Table 1 shows the baseline clinical characteristic data for the study patients. The dose of eplerenone was 25 mg/day in 10 patients (50%), and the others received eplerenone 50 mg/day. The mean dose of eplerenone was 37.5 ± 12.8 mg/day. During the intervention, eplerenone therapy was well tolerated; none of our patients required discontinuation or dose-tapering of eplerenone due to adverse effects (e.g. serum potassium > 5.5 mEq/l, hypotension, symptomatic problems).
Results
The mean changes in office and 24-h BP and pulse rate (PR) levels are shown in table 2. There was a significant reduction of the office systolic BP (-13.1 mmHg, p = 0.006), and 24-h systolic and diastolic BP levels (-11.1 and -5.4 mmHg, respectively; both p < 0.01) (table 2). There were no significant changes in office or 24-h PR levels. Because daytime and night-time systolic BP were almost equally reduced by the eplerenone treatment, the diurnal variation of the 24-h BP profile was not significantly altered. Baseline high levels of both ANP and BNP were positively associated with night-time systolic BP level (r = 0.471 and 0.532, respectively; both p < 0.05), and they were also associated with a greater reduction of 24-h systolic BP level (r = -0.453 and -0.455, respectively; both p < 0.05). In contrast, neither the baseline plasma renin and aldosterone levels, aldosterone-to-renin ratio, or baseline serum potassium level was associated with the extent of office or 24-h systolic BP reduction (data not shown).
Plasma levels of PAI-1 and ANP were significantly reduced after eplerenone treatment (table 3) . There were no significant associations between the change of PAI-1 (PAI-1 after 24 weeks minus PAI-1 at baseline) and the change of renin or aldosterone levels (table 4) . In contrast, there were significant associations between the change of ANP (ANP after 24 weeks minus ANP at baseline) and the changes of renin, 24-h systolic BP, and night-time systolic BP (all p < 0.05, table 4).
Both the plasma PIIINP level and UAE rate were significantly reduced after eplerenone treatment ( figure 1A  and 1B ), whereas the plasma ICTP level was unchanged (table 3) . There was a significant association between the change of plasma PIIINP (PIIINP after 24 weeks minus PIIINP at baseline) and the change of UAE (table 4). The change of plasma PIIINP was significantly associated with the reduction of daytime systolic BP levels, and there was a non-significant trend toward an inverse association with the change of aldosterone. In contrast, there were significant associations between the baseline UAE level and both 24-h systolic BP level (r = 0.523; p = 0.018) and night-time systolic BP level (r = 0.597; p = 0.005); however, no significant associations were found between the reduction of UAE and either 24-h systolic BP or nighttime systolic BP reduction after eplerenone treatment (table 4) .
During eplerenone treatment, there were no significant changes in body weight (56.7 ± 9.4 kg vs. 57.2 ± 9.7 kg; p = 0.129), serum creatinine level (0.7 ± 0.2 vs. 0.7 ± 0.2 mg/dl; p = 0.938), serum potassium level (4.2 ± 0.4 vs. 4.2 ± 0.4 mEq/l; p = 0.763), or serum uric acid level (5.3 ± 1.4 vs. 5.4 ± 1.7 mg/dl; p = 0.297). 
Discussion
This is the first report to demonstrate that, in elderly hypertensive patients whose BP was not controlled by ACEIs, ARBs, or other medications, the addition of eplerenone (mean 37.5 mg daily) over a 24-week period had significant benefits not only by lowering office and 24-h BP levels, but also by improving fibrinolytic activity and cardio-renal protection. In the present study, eplerenone treatment was generally well tolerated, with no reports of hyperkalaemia or hypotension. Eplerenone (25 mg or 50 mg once daily), when added to the drug regimen of patients who were already using an average of 2.4 anti-hypertensive drugs, lowered office systolic/diastolic BP by an average of 13.1/4.5 mmHg and 24-h systolic/diastolic BP by an average of 11.1/5.4 mmHg. In the present study, all patients were taking ACEIs or ARBs, and the addition of eplerenone to the treatment regimen further decreased BP, suggesting that ACEIs or ARB did not adequately suppress aldosterone. [8] [9] [10] Physiologically, aldosterone contributes to sodium absorption, which in turn results in intravascular volume expansion; thus, theoretically, the anti-hypertensive effects of eplerenone treatment may be due to the reduction of sodium retention as well as the reduction of intravascular volume expansion. In fact, in the present study there were significant associations between the reduction of 24-h systolic BP level (particularly night-time BP level) and the reduction of ANP or BNP levels by eplerenone treatment (table 4). It is known that ANP is mainly produced in the cardiac atria, and BNP is produced in the cardiac ventricles in response to volume load or pressure load, 21 and thus our data suggest at least two possibilities: first, the BP reduction realised by eplerenone treatment may have been at least partly due to a reduction in intravascular volume; second, the reduction of ANP or BNP levels may have been merely a marker of the reduction of cardiac afterload (i.e. pressure load) by the BP-lowering effect of eplerenone. 22 Much as in our previous reports, 23 our present patients with high baseline ANP and BNP levels were likely to have a high night-time systolic BP level, which strengthens the previous findings that persistent intravascular volume Table 4 . Association between the change of BP, haemostasis, biochemical, and cardiovascular parameters before and after eplerenone treatment (n = 20) expansion is an important cause of uncontrolled BP, 24 and particularly uncontrolled night-time BP levels, 25 in hypertensive patients treated with anti-hypertensive agents that included ACEIs and ARBs 26 ; eplerenone may represent a more reasonable approach in such cases. However, in the present study, no significant differences were found in body weight, serum potassium level, or serum uric acid level between before and after eplerenone treatment. Moreover, consistent with previous reports, 27, 28 the baseline plasma aldosterone level was within normal range and no significant association was found between the BP-lowering effect of eplerenone and circulatory RAAS levels. This means, as suggested by Levy et al., 28 that the anti-hypertensive effect of eplerenone occurs via mechanisms other than a diuretic action (e.g. via the action of non-epithelial mineralocorticoid receptor (MR)), and this anti-hypertensive effect was independent of circulatory RAAS activity. Further research will be needed to evaluate more subtle changes in the patients' fluids, electrolyte status, and 24-h aldosterone production after eplerenone treatment, as well as the possibility that non-epithelial MR activity (e.g. brain and vascular MR activity) is involved in the increase in BP. PAI-1 is not only the major physiological inhibitor of fibrinolysis in vivo but also contributes directly to the progression of atherosclerosis and CVDs. Although the effects of activated RAAS on hypofibrinolysis have been attributed to angiotensin II, increasing evidence suggests that aldosterone also increases PAI-1 expression. 11, 12 In fact, the plasma PAI-1 level has been associated with the serum aldosterone level in hypertensive patients, and this association was abolished by aldosterone blockade. 12 In the present study, 18 patients (90%) used ARBs; while ACEIs are known to reduce the PAI-1 level, the effect of ARBs on the PAI-1 level has been a matter of controversy. 11, 29 Although short-term ARB treatment decreases PAI-1 antigen, prolonged ARB treatment does not. 29 The mechanisms by which ARBs lose their ability to decrease PAI-1 over time are unknown, but aldosterone breakthrough may be one possible explanation. Although such a possibility could not be addressed in the present study, our data support the previous finding 30 that combination therapy with ARBs and eplerenone is more effective for PAI-l reduction than ARBs alone.
The cardiac extracellular matrix undergoes extensive and continuous turnover during cardiac remodelling, during hypertensive cardiac hypertrophy, and especially during its transition to heart failure, 31 and all of these processes are influenced by aldosterone. 13, 19, 31 A previous human study showed that there was a positive association between transcardiac extraction of aldosterone and the plasma level of PIIINP, 19 and spironolactone therapy decreased plasma PIIINP in patients with heart failure even though they received ACEIs. 32 Taken together with our present findings, these results suggest that combination therapy with eplerenone and ACEIs or ARBs, rather than monotherapy with ACEIs or ARBs, could be more favourable for reducing cardiac collagen turnover not only in the failing heart but also the hypertensive heart. Our results have important clinical implications for the management of hypertension, because the reduction of cardiac collagen turnover biomarkers by anti-hypertensive drugs is associated with the regression of myocardial fibrosis. 33 Our results showed that the reduction of plasma PIIINP level was significantly associated with daytime systolic BP reduction, which means that lowering BP is a major factor in reducing the PIIINP level. In contrast, there was a tendency, albeit not a statistically significant one, toward an inverse association between the reduction of plasma PIIINP level and the change of aldosterone after eplerenone treatment (table 4). The lack of significance in this correlation may have been due to the small sample size; and thus, the observed tendency may support the previous finding 19 that a more potent aldosterone blockade (accompanied with loss of feedback inhibition of aldosterone production) could lead to a reduction of cardiac collagen turnover. Alternatively, because the baseline aldosterone levels of our patients were not elevated, it may be that the cardioprotective role of eplerenone treatment was derived from the blocking effects of hormones other than aldosterone. Recent evidence from experimental in vivo studies suggests that cardiac MRs are activated by not only circulating aldosterone but also cortisol levels in situations in which reactive oxygen species are generated and/or the intracellular redox status is altered (e.g., hypertension or heart failure). [34] [35] [36] Accordingly, there may be a possibility that the cardioprotective role of eplerenone treatment is derived from the blocking effects of cortisol on MR activation in hypertensive patients. The addition of spironolactone or eplerenone to ACEIs and/ or ARBs has been reported to reduce proteinuria by an additional 30-40% over the baseline treatment in patients with diabetes and chronic kidney disease, and these results were partly attributed to aldosterone breakthrough. 8, 9, 37 In our study, the baseline UAE level was associated with 24-h systolic BP level, and particularly with night-time systolic BP level; which confirms the previous findings that an uncontrolled BP level, and particularly an uncontrolled night-time BP level, is an important component of incomplete renal protection in patients using ACEIs or ARBs. 25, 38 However, unlike in these reports, we found no association between the reduction of UAE and the nocturnal BP level reduction after eplerenone treatment in the present study. Intriguingly, there was a significant association between the reduction of UAE and the reduction of plasma PIIINP level in our patients (table 4), which means that the impact of eplerenone on renal (or vascular) protection was associated with a consistent impact on cardiac protection.
The major limitation of our study was its small sample size and the lack of a placebo control. Hence, at least in theory, the observed BP reduction might be explained or influenced by factors other than the treatment itself, including acclimatisation, regression to the mean, or a placebo-like effect. In addition, our study was too small to assess safety in a definitive fashion. Although we encountered few problems with adding eplerenone to ACEIs or ARBs even in elderly hypertensive patients at the low dose selected, it is unlikely that such therapy should be used except in closely monitored patients.
In conclusion, our study demonstrated that, in elderly hypertensive patients whose BP was not controlled by ACEIs, ARBs, or other anti-hypertensive medications, addition of low-dose eplerenone to ACEIs or ARBs significantly improved 24-h BP levels, fibrinolytic activity, and cardio-renal protection. Further studies with a larger sample size will be needed to elucidate the long-term effects of combination therapy with eplerenone and ACEIs or ARBs on hypertension-related organ damage, and CVD morbidity and mortality in a hypertensive population.
